Adaptive Biotech director sells 30K shares
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg reported an option exercise and related share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp (ADPT) director Robert Hershberg reported an option exercise and related share sales. On 2026-08-18, he exercised a stock option for 15,000 shares of common stock at an exercise price of $6.32 per share, fully using an option that would have expired on October 18, 2026. He then sold 30,664 shares of common stock in two transactions at weighted average prices of $24.39 and $24.41 per share, with actual sale prices ranging from $24.38–$24.44 as disclosed in the footnotes.
Insights
Analyzing...
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
HERSHBERG ROBERT
Role
Director
Sold
30,664 shs ($748K)
Approx. gross sale proceeds
$748K
Approx. exercise cost
$95K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F3 | 15,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 15,000 | $6.32 | $95K |
| Sale | Common Stock F1 | 15,000 | $24.39 | $366K |
| Sale | Common Stock F2 | 15,664 | $24.41 | $382K |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 46,683 shares (Direct)
Footnotes (3)
- F1. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The option was fully vested and exercisable and would have expired on October 18, 2026.
Key Figures
Option shares exercised: 15,000 shares
Option exercise price: $6.32 per share
Option shares following transaction: 0 shares
+3 more
6 metrics
Option shares exercised
15,000 shares
Stock Option (right to buy) for common stock exercised on 2026-08-18
Option exercise price
$6.32 per share
Exercise price for 15,000-share stock option exercised on 2026-08-18
Option shares following transaction
0 shares
Total shares following transaction for this option grant
Shares sold at $24.39 weighted average
15,000 shares
Common stock sale on 2026-08-18; actual prices $24.38–$24.43
Shares sold at $24.41 weighted average
15,664 shares
Common stock sale on 2026-08-18; actual prices $24.40–$24.44
Total shares sold
30,664 shares
Aggregate common stock sold across both sale transactions
Key Terms
weighted average price, Stock Option (right to buy, derivative security
3 terms
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy financial
"security_title": "Stock Option (right to buy)"
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ADPT director Robert Hershberg report on this Form 4?
He reported exercising a stock option for 15,000 shares of Adaptive Biotechnologies Corp common stock at an exercise price of $6.32 per share and selling a total of 30,664 shares of common stock in two separate sale transactions on 2026-08-18.
How many Adaptive Biotechnologies (ADPT) options did Hershberg exercise?
He exercised a stock option covering 15,000 shares of Adaptive Biotechnologies Corp common stock at an exercise price of $6.32 per share. Following the exercise, the reported option position for this grant was 0 shares, and the option was described as fully vested and exercisable.
What do the weighted average prices mean in this ADPT Form 4?
The filing states that the reported per-share prices of $24.39 and $24.41 are weighted average prices. The shares were sold in multiple transactions at prices ranging from $24.38–$24.43 and $24.40–$24.44, respectively, and detailed trade-by-trade information is available on request.
Was the exercised ADPT option still vesting or already vested?
The filing states that the option was fully vested and exercisable and would have expired on October 18, 2026. After the reported exercise of 15,000 shares, the remaining reported balance for this option grant was 0 shares.
Does this ADPT Form 4 indicate trades under a Rule 10b5-1 plan?
The document-level Rule 10b5-1 checkbox is reported as false, and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 trading plan. The filing does not describe these trades as pre-arranged under such a plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
